Jounce Therapeutics — Investor Presentation (November 2018)
29 slides from Jounce Therapeutics's investor presentation, Nov 9, 2018

Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company
Exhibit 99.1 Jounce Therapeutics A Next Gen Immunotherapy Company

Slide 2: Legal Disclaimer
Legal Disclaimer Various statements concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of research and development programs, preclinical studies and clinical trials for Jounce’s product candidat

Slide 3: Delivering Value, Pipeline Execution, Approach & IO Opportunity
DELIVERING VALUE PIPELINE EXECUTION APPROACH & IO OPPORTUNITY 3 | Jounce Therapeutics © November 2018

Slide 4: Delivering Value, Pipeline Execution, Approach & IO Opportunity
DELIVERING VALUE PIPELINE EXECUTION APPROACH & IO OPPORTUNITY 4 | Jounce Therapeutics © November 2018

Slide 5: What Makes Jounce Different?
What Makes Jounce Different? Robust Translational Science Platform Diverse, Broad Pipeline • Engine to drive sustained discovery • Three development programs – JTX-2011 (anti-ICOS) Phase 1/2 • Programs targeting multiple immune cell types – JTX-4014 (anti-PD-1) IND active – JTX-8064 (anti-LILRB2) tr

Slide 6: Immunotherapy Opportunities Beyond PD-1 Inhibitors
Immunotherapy Opportunities Beyond PD-1 Inhibitors 100% 90% Untapped Therapeutic Opportunity 80% • Unmet need remains high with most patients not responding 70% • Biomarkers make a difference: NSCLC, MSI-H 60% • Response rates go down in later lines of therapy 50% 40% 30% 20% ORR for FDA Approved An

Slide 7: The IO Challenge: Emerging, Complex Treatment Paradigm
The IO Challenge: Emerging, Complex Treatment Paradigm • The immunity cycle is complex: CTLA-4i – Role and impact of PD-1 just emerging • Challenges to current IO approach: – Repurposing molecules/mechanisms – Testing with limited rationale – Combination failures – Elusive biomarkers – Shifting pati

Slide 8: The Jounce Solution: Next Generation IO
The Jounce Solution: Next Generation IO Tumor Immune Composition • Strong scientific foundation: – Understanding where IO mechanisms act within the immunity cycle – Founders and leadership expertise in checkpoint and IO Discover 1st in Class Therapies biology • Unique approach: – Robust translationa

Slide 9: Delivering Value, Pipeline Execution, Approach & IO Opportunity
DELIVERING VALUE PIPELINE EXECUTION APPROACH & IO OPPORTUNITY 9 | Jounce Therapeutics © November 2018

Slide 10: Jounce Immunotherapy Pipeline
Jounce Immunotherapy Pipeline Development Programs Clinical Program Target Preclinical Phase 1 Phase 2 Phase 3 JTX-2011 ICOS JTX-4014 PD-1 JTX-8064 LILRB2 Research Programs Named Celgene Option Celgene Target Pool Target Rights Stromal Jounce Wholly-owned Macrophage, B-cell, T-reg Celgene Target Poo

Slide 11: Translational and Reverse Translational Analysis
Translational and “Reverse” Translational Analysis Identify Mechanistic and Predictive Biomarkers Mechanistic, biomarker and combination approaches evolve through development Preclinical Data / Hypothesis Clinical Trial Patient Samples Drive Next Steps • Preclinical discovery and model systems • Ana

Slide 12: Development Programs: JTX-2011
Development Programs JTX-2011 JTX-4014 JTX-8064 12 | Jounce Therapeutics © November 2018

Slide 13: JTX-2011 Mechanism From Preclinical Studies
JTX-2011 Mechanism From Preclinical Studies Activation of T effector cells IFN-Y IFN-Y APC APC IFN-Y IFN-Y 1st1stsignalsignalICOS TCR JTX-2011 TCR TCR ICOS ↑↑IFN-γ ICOS ICOS “Non-Primed” “Primed” T effector cell T effector cell TNK regulatory cell cell T regulatory cell Selective reduction of intrat

Slide 14: JTX-2011: Key Learnings from Phase 1/2 ICONIC Trial
JTX-2011: Key Learnings from Phase 1/2 ICONIC Trial Safety • JTX-2011 safe and well tolerated alone and in combination with nivo Preliminary Efficacy • Responses in both monotherapy and in combination with nivo – Durable (PR ≥ 6 months) RECIST PRs in PD-1 inhibitor naïve patients – Tumor reductions

Slide 15: Importance of ICOS hi CD4 T Cells
Importance of ICOS hi CD4 T Cells Clinical Trial Patient Samples Drive Preclinical Data / Hypothesis Next Steps Tumor Reverse translational work from responders versus non-responders • ICONIC patient enrichment: • ICOS hi CD4 T cells emerged in the blood in – Patients screened for ICOS(+) immune cel

Slide 16: JTX-2011: Key Learnings from ICONIC Reverse Translational Work
JTX-2011: Key Learnings from ICONIC Reverse Translational Work Mechanism • ICOS hi CD4 T cells emerge upon treatment with JTX- CTLA-4i 2011 JTX-2011 • Emergence of ICOS hi CD4 T cells is correlated to response • JTX-2011 only activates CD4 T cells if they already express high levels of ICOS Combinat

Slide 17: JTX-2011 Ongoing Studies and Next Steps
JTX-2011 Ongoing Studies and Next Steps Phase 1 Phase 2 Safety Preliminary Efficacy Ipilimumab Dose Escalation combo - New combination • Phase 2 combinations anticipated in 2019 - Strong scientific rationale • Multiple cohorts and regimens • Earlier lines of therapy Pembrolizumab Dose Escalation com

Slide 18: Development Programs: JTX-4014
Development Programs JTX-2011 JTX-4014 JTX-8064 18 | Jounce Therapeutics © November 2018

Slide 19: JTX-4014: Anti-PD-1 Program On Track
JTX-4014: Anti-PD-1 Program On Track • IND filed Sept 2018 • Study May Proceed letter received Oct 2018 Well-characterized anti-PD-1 antibody Monotherapy safety and POC • Fully human IgG4 • For use in combinations with potential • Blocks binding to PD-L1 and PD-L2 future product candidates 19 | Joun

Slide 20: Development Programs: JTX-8064
Development Programs JTX-2011 JTX-4014 JTX-8064 20 | Jounce Therapeutics © November 2018

Slide 21: LILRB2 Binds HLA-G and MHC I Suppressing Macrophages
LILRB2 Binds HLA-G and MHC I Suppressing Macrophages (M2-like) JTX-8064 Blocks the Interaction with Both Ligands Tumor LILRB2 (aka ILT4) HLA-G JTX-8064 MHC I M1-like Macrophage M2-like Macrophage 21 | Jounce Therapeutics © November 2018

Slide 22: LILRB2 Antibodies Reprogram Tumor Associated Macrophages
LILRB2 Antibodies Reprogram Tumor Associated Macrophages Pro-Inflammatory Anti-Inflammatory • TNF • CCL2 • IL-1 • IL-10 LILRB2 antibodies promote M1-like activation LILRB2 antibodies attenuate M2-like activation Control mAb JTX-mAb-1 produced JTX-mAb-1 IL-10 produced TNF (relative alone)LPS to (re

Slide 23: Deletion of Tumor LILRB2 Reduces Growth of Macrophage-Rich Tumors
Deletion of Tumor LILRB2 Results in Reduced Growth of Macrophage- Rich Tumors Mouse expressing normal PirB target (human LILRB2) Mouse lacking PirB target (human LILRB2) MC38 tumor (macrophage staining) WT MC38 PirB MC38 3500 3500 3000 3000 2500 2500 2000 2000 1500 1500 1000 1000 500 500 Tumor Volum

Slide 24: Jounce Immunotherapy Pipeline
Jounce Immunotherapy Pipeline Development Programs Clinical Program Target Preclinical Phase 1 Phase 2 Phase 3 JTX-2011 ICOS JTX-4014 PD-1 JTX-8064 LILRB2 Research Programs Named Celgene Option Celgene Target Pool Target Rights Stromal Jounce Wholly-owned Macrophage, B-cell, T-reg Celgene Target Poo

Slide 25: Delivering Value, Pipeline Execution, Approach & IO Opportunity
DELIVERING VALUE PIPELINE EXECUTION APPROACH & IO OPPORTUNITY 25 | Jounce Therapeutics © November 2018

Slide 26: Jounce and Celgene Strategic Collaboration
Jounce and Celgene Strategic Collaboration Co-develop and Co-commercialize Innovative Immunotherapies Collaboration Highlights • Global strategic collaboration, enabling comprehensive clinical strategy Committed to working together • Option based deal, preset opt-in fees and profit share, cost shari

Slide 27: Financial Strength and Flexibility
Financial Strength and Flexibility Company History • NASDAQ: JNCE • Strength of balance sheet: Event Date Gross $ Comment – ~$233M cash and investments, Series A 2013 $47M Third Rock as of June 30, 2018 Ventures • Financial guidance for 2018: Series B 2015 $56M Fidelity, Wellington, others – End yea

Slide 28: 2018 Milestones
2018 Milestones Report JTX-2011 preliminary clinical efficacy results in Q2 Initiate new JTX-2011 combination (anti-CTLA-4) Advance next development candidate into IND enabling activities Submit IND for JTX-4014 (anti-PD-1) 28 | Jounce Therapeutics © November 2018

Slide 29: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Source: SEC EDGAR · 8-K filed Nov 9, 2018
More decks from Jounce Therapeutics Inc
Investor Presentation (August 2022)34 slides · Aug 30, 2022
Investor Presentation (March 2022)33 slides · Mar 7, 2022
Investor Presentation (January 2022)31 slides · Jan 10, 2022
Investor Presentation (January 2021)26 slides · Jan 11, 2021
Investor Presentation (April 2020)28 slides · Apr 7, 2020
Investor Presentation (January 2020)26 slides · Jan 13, 2020